{
    "hands_on_practices": [
        {
            "introduction": "Understanding the time course of a drug in the body is the cornerstone of pharmacology. Key parameters like the elimination half-life ($t_{1/2}$), the time required to reach steady state, and the degree of drug accumulation with repeated dosing dictate how a therapeutic agent should be administered to be both effective and safe. This first exercise challenges you to derive these fundamental pharmacokinetic properties from first principles, providing a solid foundation for designing and evaluating dosing regimens for targeted therapies. ",
            "id": "4575193",
            "problem": "A patient is prescribed an oral tyrosine kinase inhibitor (TKI; tyrosine kinase inhibitor) dosed once daily (QD; once daily), and its pharmacokinetics are well described by a linear one-compartment model with first-order elimination and negligible absorption time relative to elimination. The fundamental pharmacokinetic base you should use comprises: (i) mass balance in a single well-mixed compartment where the rate of change of concentration is proportional to the concentration, (ii) the definition of clearance as the proportionality constant relating elimination rate to concentration, and (iii) the definition of volume of distribution as the proportionality constant relating amount in the body to concentration. From these principles, derive the expression for the elimination half-life in terms of volume of distribution and clearance, then evaluate it for a TKI with volume of distribution $V_d=200$ L and clearance $CL=10$ L/h. Next, using the same base, determine the time required to reach $95\\%$ of the asymptotic steady state under repeated dosing, operationally defined as the time $t$ at which the fraction to steady state, governed solely by the elimination rate constant, equals $0.95$. Finally, derive the accumulation index for once-daily dosing with dosing interval $\\tau=24$ h, defined as the ratio of the steady-state concentration profile to the single-dose concentration profile at the same post-dose time under linear kinetics, and evaluate it numerically for the given parameters. Round all numerical answers to four significant figures. Express time quantities in hours and report the accumulation index as a dimensionless quantity. Provide your three numerical results in the order: half-life, time to $95\\%$ steady state, accumulation index.",
            "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, and objective. It is based on fundamental and standard principles of pharmacokinetics. All necessary parameters and definitions are provided, and there are no internal contradictions or unrealistic assumptions. The problem is valid for solution.\n\nThe solution is structured into three parts as requested: derivation and calculation of the elimination half-life ($t_{1/2}$), the time to reach $95\\%$ of steady state ($t_{95\\%SS}$), and the accumulation index ($R_{ac}$).\n\n**Part 1: Elimination Half-Life ($t_{1/2}$)**\n\nThe derivation begins from the fundamental principles provided.\n(i) The mass balance for a drug in a single well-mixed compartment states that the rate of change of the amount of drug in the body, $A(t)$, is equal to the rate of drug in minus the rate of drug out. For the post-absorptive phase, the rate in is zero, and the rate out is the elimination rate.\n(ii) The elimination rate is given by the product of clearance, $CL$, and the plasma concentration, $C(t)$.\nCombining these, the differential equation for the amount of drug in the body is:\n$$\n\\frac{dA(t)}{dt} = - \\text{Rate of Elimination} = -CL \\cdot C(t)\n$$\n(iii) The volume of distribution, $V_d$, relates the amount of drug in the body to its concentration:\n$$\nA(t) = V_d \\cdot C(t)\n$$\nDifferentiating this relationship with respect to time $t$ gives:\n$$\n\\frac{dA(t)}{dt} = V_d \\frac{dC(t)}{dt}\n$$\nBy substituting this into the mass balance equation, we obtain a differential equation for concentration:\n$$\nV_d \\frac{dC(t)}{dt} = -CL \\cdot C(t)\n$$\nRearranging this equation shows that the rate of change of concentration is proportional to concentration, as stated in principle (i):\n$$\n\\frac{dC(t)}{dt} = -\\left(\\frac{CL}{V_d}\\right) C(t)\n$$\nThis equation describes first-order elimination. The proportionality constant is the first-order elimination rate constant, $k_e$:\n$$\nk_e = \\frac{CL}{V_d}\n$$\nThe differential equation is $\\frac{dC(t)}{dt} = -k_e C(t)$. This is a separable differential equation. Let $C(0) = C_0$ be the initial concentration at time $t=0$.\n$$\n\\int_{C_0}^{C(t)} \\frac{dC}{C} = \\int_{0}^{t} -k_e dt\n$$\n$$\n\\ln(C(t)) - \\ln(C_0) = -k_e t\n$$\n$$\n\\ln\\left(\\frac{C(t)}{C_0}\\right) = -k_e t\n$$\n$$\nC(t) = C_0 \\exp(-k_e t)\n$$\nThe elimination half-life, $t_{1/2}$, is the time required for the concentration to decrease to one-half of its initial value, i.e., $C(t_{1/2}) = \\frac{1}{2}C_0$.\n$$\n\\frac{1}{2}C_0 = C_0 \\exp(-k_e t_{1/2})\n$$\n$$\n\\frac{1}{2} = \\exp(-k_e t_{1/2})\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k_e t_{1/2}\n$$\n$$\n-\\ln(2) = -k_e t_{1/2}\n$$\n$$\nt_{1/2} = \\frac{\\ln(2)}{k_e}\n$$\nSubstituting the expression for $k_e$ in terms of $V_d$ and $CL$:\n$$\nt_{1/2} = \\frac{\\ln(2)}{CL / V_d} = \\frac{V_d \\ln(2)}{CL}\n$$\nNow, we evaluate this expression using the given values $V_d = 200$ L and $CL = 10$ L/h.\n$$\nt_{1/2} = \\frac{200~\\text{L} \\cdot \\ln(2)}{10~\\text{L/h}} = 20 \\ln(2)~\\text{h} \\approx 13.8629~\\text{h}\n$$\nRounding to four significant figures, $t_{1/2} = 13.86$ h.\n\n**Part 2: Time to Reach $95\\%$ of Steady State ($t_{95\\%SS}$)**\n\nThe attainment of steady state during a multiple-dosing regimen is an asymptotic process governed by the elimination rate constant, $k_e$. The problem defines the fraction to steady state at time $t$ as $1 - \\exp(-k_e t)$. We are asked to find the time $t_{95\\%SS}$ at which this fraction equals $0.95$.\n$$\n1 - \\exp(-k_e t_{95\\%SS}) = 0.95\n$$\nSolving for $t_{95\\%SS}$:\n$$\n\\exp(-k_e t_{95\\%SS}) = 1 - 0.95 = 0.05\n$$\nTaking the natural logarithm of both sides:\n$$\n-k_e t_{95\\%SS} = \\ln(0.05)\n$$\n$$\nt_{95\\%SS} = \\frac{-\\ln(0.05)}{k_e} = \\frac{\\ln\\left(\\frac{1}{0.05}\\right)}{k_e} = \\frac{\\ln(20)}{k_e}\n$$\nFirst, we calculate $k_e$:\n$$\nk_e = \\frac{CL}{V_d} = \\frac{10~\\text{L/h}}{200~\\text{L}} = 0.05~\\text{h}^{-1}\n$$\nNow we can evaluate $t_{95\\%SS}$:\n$$\nt_{95\\%SS} = \\frac{\\ln(20)}{0.05~\\text{h}^{-1}} \\approx \\frac{2.995732}{0.05}~\\text{h} \\approx 59.9146~\\text{h}\n$$\nRounding to four significant figures, $t_{95\\%SS} = 59.91$ h. This corresponds to approximately $4.32$ half-lives, which is a common rule-of-thumb time to achieve clinical steady state.\n\n**Part 3: Accumulation Index ($R_{ac}$)**\n\nThe accumulation index, $R_{ac}$, is defined as the ratio of the steady-state concentration profile to the single-dose concentration profile. For a linear system, this ratio is constant for all times $t$ within a dosing interval ($0 \\le t < \\tau$).\n$$\nR_{ac} = \\frac{C_{SS}(t)}{C_1(t)}\n$$\nAssuming a dose $D$ is administered as an IV bolus (negligible absorption time), the concentration after a single dose is:\n$$\nC_1(t) = C_0 \\exp(-k_e t) = \\frac{D}{V_d} \\exp(-k_e t)\n$$\nAt steady state with repeated dosing every interval $\\tau$, the concentration at time $t$ after the most recent dose is the sum of the drug remaining from an infinite series of prior doses:\n$$\nC_{SS}(t) = \\frac{D}{V_d} \\exp(-k_e t) + \\frac{D}{V_d} \\exp(-k_e (t+\\tau)) + \\frac{D}{V_d} \\exp(-k_e (t+2\\tau)) + \\dots\n$$\nFactoring out the common terms:\n$$\nC_{SS}(t) = \\frac{D}{V_d} \\exp(-k_e t) \\left[ 1 + \\exp(-k_e \\tau) + \\exp(-2k_e \\tau) + \\dots \\right]\n$$\nThe term in brackets is an infinite geometric series $\\sum_{n=0}^{\\infty} r^n$ with the common ratio $r = \\exp(-k_e \\tau)$. Since $k_e > 0$ and $\\tau > 0$, the ratio $r$ is between $0$ and $1$, and the series converges to $\\frac{1}{1-r}$.\n$$\n\\sum_{n=0}^{\\infty} (\\exp(-k_e \\tau))^n = \\frac{1}{1 - \\exp(-k_e \\tau)}\n$$\nTherefore, the steady-state concentration profile is:\n$$\nC_{SS}(t) = \\left( \\frac{D}{V_d} \\exp(-k_e t) \\right) \\left( \\frac{1}{1 - \\exp(-k_e \\tau)} \\right)\n$$\nWe can now calculate $R_{ac}$:\n$$\nR_{ac} = \\frac{C_{SS}(t)}{C_1(t)} = \\frac{\\left( \\frac{D}{V_d} \\exp(-k_e t) \\right) \\left( \\frac{1}{1 - \\exp(-k_e \\tau)} \\right)}{\\frac{D}{V_d} \\exp(-k_e t)} = \\frac{1}{1 - \\exp(-k_e \\tau)}\n$$\nThis confirms that for a linear system, the accumulation index is independent of dose $D$, volume $V_d$, and time post-dose $t$. It depends only on the elimination rate constant $k_e$ and the dosing interval $\\tau$.\nWe now evaluate this numerically with $k_e = 0.05~\\text{h}^{-1}$ and $\\tau = 24$ h.\nThe product $k_e \\tau$ is:\n$$\nk_e \\tau = (0.05~\\text{h}^{-1})(24~\\text{h}) = 1.2\n$$\nThe accumulation index is then:\n$$\nR_{ac} = \\frac{1}{1 - \\exp(-1.2)} \\approx \\frac{1}{1 - 0.3011942} = \\frac{1}{0.6988058} \\approx 1.430999\n$$\nRounding to four significant figures, $R_{ac} = 1.431$. This is a dimensionless quantity.\n\nThe three requested numerical results in order are:\n1.  Half-life: $13.86$ h\n2.  Time to $95\\%$ steady state: $59.91$ h\n3.  Accumulation index: $1.431$",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 13.86 & 59.91 & 1.431 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "For orally administered drugs like many tyrosine kinase inhibitors, the journey begins with dissolution in the gastrointestinal tract, a process highly sensitive to local pH. As many TKIs are weak bases, their solubility can be drastically altered by changes in gastric acidity, a common scenario for cancer patients who may be taking acid-reducing agents. This practice delves into the physicochemical principles of pH-dependent solubility, allowing you to quantify the impact of a common drug-drug interaction and appreciate its clinical significance for bioavailability. ",
            "id": "4575259",
            "problem": "A clinical pharmacologist is evaluating a new tyrosine kinase inhibitor (TKI) that is a monoprotic weak base with acid dissociation constant $pK_a = 5.5$ and intrinsic solubility $S_0 = 0.05$ mg/mL. The intrinsic solubility $S_0$ is the saturation concentration of the neutral base in the absence of ionization. Assume ideal solution behavior (activity coefficients near unity), no complex precipitation or salt-limited solubility, and that only the singly protonated species forms in the clinically relevant pH range. The gastric pH under fasting conditions is $2$, but a coadministered proton pump inhibitor (PPI) may raise gastric pH to $5$.\n\nStarting from the acid–base equilibrium of a monoprotic weak base and the definition of $pK_a$, and using the concept that the ionized fraction contributes additively to the apparent solubility of a weak base, derive the relationship between total solubility $S_{\\text{total}}$ and pH in terms of $S_0$, $pK_a$, and pH. Then use it to compute the total solubility at pH = 2 and at pH = 5 in mg/mL. Finally, report as your answer the fold-change in solubility upon PPI coadministration, defined as the ratio $S_{\\text{total}}(\\mathrm{pH}=5)/S_{\\text{total}}(\\mathrm{pH}=2)$, expressed as a decimal with no units. Round your final ratio to three significant figures.",
            "solution": "The user-provided problem is evaluated against the validation criteria.\n\n### Step 1: Extract Givens\n- Drug is a monoprotic weak base.\n- Acid dissociation constant of the conjugate acid: $pK_a = 5.5$.\n- Intrinsic solubility of the neutral base: $S_0 = 0.05$ mg/mL.\n- Assumptions: ideal solution behavior, no complex precipitation or salt-limited solubility, only singly protonated species forms.\n- Fasting gastric pH: $\\mathrm{pH}_{\\text{fasting}} = 2$.\n- Gastric pH with proton pump inhibitor (PPI): $\\mathrm{pH}_{\\text{PPI}} = 5$.\n- Task 1: Derive the relationship between total solubility $S_{\\text{total}}$ and $\\mathrm{pH}$ in terms of $S_0$, $pK_a$, and $\\mathrm{pH}$.\n- Task 2: Compute $S_{\\text{total}}$ at $\\mathrm{pH} = 2$.\n- Task 3: Compute $S_{\\text{total}}$ at $\\mathrm{pH} = 5$.\n- Task 4: Compute the fold-change ratio $S_{\\text{total}}(\\mathrm{pH}=5) / S_{\\text{total}}(\\mathrm{pH}=2)$.\n- Reporting requirement: Final ratio as a decimal rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, describing the well-established principle of pH-dependent solubility for ionizable compounds. This is a fundamental concept in pharmaceutics and pharmacology. The provided values ($pK_a$, $S_0$, $\\mathrm{pH}$ levels) are realistic for a clinical scenario involving an oral drug. The problem is well-posed, providing all necessary data and explicit assumptions to allow for a unique, stable solution. The terminology is precise and objective. The problem does not violate any of the invalidity criteria.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A reasoned solution will be provided.\n\n### Solution Derivation and Calculation\n\nThe problem requires the derivation of the total solubility ($S_{\\text{total}}$) of a monoprotic weak base as a function of $\\mathrm{pH}$. Let the weak base be represented by the symbol $B$ and its protonated (conjugate acid) form by $BH^+$.\n\nThe relevant chemical equilibrium is the dissociation of the conjugate acid, for which the $pK_a$ is given:\n$$BH^+ \\rightleftharpoons B + H^+$$\n\nThe acid dissociation constant, $K_a$, is defined by the mass-action expression for this equilibrium:\n$$K_a = \\frac{[B][H^+]}{[BH^+]}$$\nwhere the brackets denote molar concentrations. The problem assumes ideal behavior, so activities are replaced by concentrations.\n\nThe total solubility, $S_{\\text{total}}$, is the maximum total concentration of the drug that can be dissolved in the solution at a given $\\mathrm{pH}$. It is the sum of the concentrations of all dissolved species at saturation:\n$$S_{\\text{total}} = [B]_{\\text{sat}} + [BH^+]_{\\text{sat}}$$\n\nA key principle of solubility for ionizable compounds is that the concentration of the neutral, unionized species in a saturated solution is constant and equal to its intrinsic solubility, $S_0$, regardless of the $\\mathrm{pH}$. Therefore, at saturation:\n$$[B]_{\\text{sat}} = S_0$$\n\nNow, we can express the concentration of the protonated species, $[BH^+]_{\\text{sat}}$, in terms of $S_0$. Rearranging the $K_a$ expression and substituting $[B]_{\\text{sat}} = S_0$:\n$$[BH^+]_{\\text{sat}} = \\frac{[B]_{\\text{sat}}[H^+]}{K_a} = \\frac{S_0[H^+]}{K_a}$$\n\nSubstituting the expressions for $[B]_{\\text{sat}}$ and $[BH^+]_{\\text{sat}}$ back into the equation for $S_{\\text{total}}$:\n$$S_{\\text{total}} = S_0 + \\frac{S_0[H^+]}{K_a}$$\n\nFactoring out $S_0$ yields the relationship between total solubility, intrinsic solubility, and hydrogen ion concentration:\n$$S_{\\text{total}} = S_0 \\left(1 + \\frac{[H^+]}{K_a}\\right)$$\n\nTo express this relationship in terms of $\\mathrm{pH}$ and $pK_a$, we use the definitions $\\mathrm{pH} = -\\log_{10}([H^+])$ and $pK_a = -\\log_{10}(K_a)$. This means $[H^+] = 10^{-\\mathrm{pH}}$ and $K_a = 10^{-pK_a}$. The ratio becomes:\n$$\\frac{[H^+]}{K_a} = \\frac{10^{-\\mathrm{pH}}}{10^{-pK_a}} = 10^{(pK_a - \\mathrm{pH})}$$\n\nSubstituting this into the solubility equation gives the final derived relationship:\n$$S_{\\text{total}} = S_0 (1 + 10^{(pK_a - \\mathrm{pH})})$$\n\nThis is the Henderson-Hasselbalch equation adapted for the solubility of a weak base.\n\nNext, we use this derived formula to compute the solubilities at the specified $\\mathrm{pH}$ values, using the given parameters $S_0 = 0.05$ mg/mL and $pK_a = 5.5$.\n\n**Solubility at $\\mathrm{pH} = 2$ (fasting gastric conditions):**\n$$S_{\\text{total}}(\\mathrm{pH}=2) = S_0 (1 + 10^{(5.5 - 2)}) = 0.05 \\times (1 + 10^{3.5})$$\n\n**Solubility at $\\mathrm{pH} = 5$ (with PPI coadministration):**\n$$S_{\\text{total}}(\\mathrm{pH}=5) = S_0 (1 + 10^{(5.5 - 5)}) = 0.05 \\times (1 + 10^{0.5})$$\n\nThe problem asks for the fold-change in solubility, defined as the ratio $S_{\\text{total}}(\\mathrm{pH}=5) / S_{\\text{total}}(\\mathrm{pH}=2)$.\n$$\\text{Fold-change} = \\frac{S_{\\text{total}}(\\mathrm{pH}=5)}{S_{\\text{total}}(\\mathrm{pH}=2)} = \\frac{0.05 \\times (1 + 10^{0.5})}{0.05 \\times (1 + 10^{3.5})}$$\n\nThe $S_0$ term cancels out, simplifying the expression:\n$$\\text{Fold-change} = \\frac{1 + 10^{0.5}}{1 + 10^{3.5}}$$\n\nNow, we evaluate this expression numerically:\n$10^{0.5} = \\sqrt{10} \\approx 3.16227766$\n$10^{3.5} = 10^3 \\times 10^{0.5} \\approx 1000 \\times 3.16227766 = 3162.27766$\n\n$$\\text{Fold-change} = \\frac{1 + 3.16227766}{1 + 3162.27766} = \\frac{4.16227766}{3163.27766} \\approx 0.001315816$$\n\nRounding the final result to three significant figures, we get $0.00132$. This significant decrease in solubility upon raising the gastric $\\mathrm{pH}$ is a classic example of a drug-drug interaction mediated by gastric acid-reducing agents, a critical consideration in clinical pharmacology.",
            "answer": "$$\\boxed{0.00132}$$"
        },
        {
            "introduction": "The ultimate goal of clinical pharmacology is to optimize therapy for the individual patient. Due to significant inter-patient variability in drug absorption, metabolism, and elimination, a standard dose may lead to sub-therapeutic or toxic exposures in some individuals. This final practice simulates a common clinical scenario: using a measured steady-state drug concentration to perform a proportional dose adjustment, a core principle of therapeutic drug monitoring (TDM) that helps tailor treatment to a patient's specific pharmacokinetic profile. ",
            "id": "4575225",
            "problem": "A patient with metastatic disease is receiving a tyrosine kinase inhibitor (TKI; tyrosine kinase inhibitor) known to exhibit linear, time-invariant pharmacokinetics (PK; pharmacokinetics) within the therapeutic range. After reaching steady state on a regimen of $400$ mg once daily (dosing interval $\\tau = 24$ hours), a pre-dose (trough) plasma concentration is measured at $600$ ng/mL. The therapeutic trough target range for this TKI is $1000$ to $1500$ ng/mL. Under the assumption that steady-state trough concentration scales proportionally with the maintenance dose when bioavailability and apparent clearance remain unchanged, compute the single new total daily dose that would target the midpoint of the therapeutic range. Round your answer to three significant figures. Express the final dose in mg.\n\nIn addition, briefly discuss key caveats that limit the use of proportional dose adjustment based solely on trough concentration for TKIs, including physiologic, pharmacologic, and measurement-related considerations.",
            "solution": "The relevant fundamental base is the definition of steady state and the linearity principle in pharmacokinetics. For a drug with linear, time-invariant PK, the concentration-time profile at steady state under repeated dosing scales linearly with the input (dose or dosing rate). Specifically, for oral dosing with constant bioavailability $F$ and apparent clearance $CL$, the concentration at any time in the dosing interval can be written as\n$$\nC(t) = \\frac{F \\cdot D}{CL} \\cdot h(t;\\tau,k,V),\n$$\nwhere $D$ is the dose per interval, $\\tau$ is the dosing interval, $k$ is the elimination rate constant, $V$ is the apparent volume of distribution, and $h(t;\\tau,k,V)$ is a dimensionless function determined by the system parameters and dosing schedule. At steady state, for fixed $\\tau$, $k$, and $V$, $h(t;\\tau,k,V)$ does not depend on $D$; hence concentrations scale proportionally with $D$.\n\nThe trough concentration $C_{\\min}$ is thus proportional to $D$:\n$$\n\\frac{C_{\\min,2}}{C_{\\min,1}} = \\frac{D_{2}}{D_{1}},\n$$\nprovided $F$ and $CL$ remain unchanged and the patient is at steady state with identical timing of sampling relative to the dose.\n\nWe are given:\n- Current dose $D_{1} = 400$ mg once daily.\n- Measured steady-state trough $C_{\\min,1} = 600$ ng/mL.\n- Target trough range $1000$ to $1500$ ng/mL. To minimize the probability of overshooting or undershooting within a symmetric range, a reasonable single-point target is the midpoint,\n$$\nC_{\\text{target}} = \\frac{1000 + 1500}{2} = 1250 \\text{ ng/mL}.\n$$\n\nUsing proportionality,\n$$\n\\frac{C_{\\text{target}}}{C_{\\min,1}} = \\frac{D_{2}}{D_{1}} \\quad \\Rightarrow \\quad D_{2} = D_{1} \\cdot \\frac{C_{\\text{target}}}{C_{\\min,1}}.\n$$\nSubstitute values:\n$$\n\\frac{C_{\\text{target}}}{C_{\\min,1}} = \\frac{1250}{600} = \\frac{25}{12} \\approx 2.083333\\ldots,\n$$\nand\n$$\nD_{2} = 400 \\times \\frac{25}{12} = \\frac{10000}{12} \\approx 833.333\\ldots \\text{ mg}.\n$$\nRounded to three significant figures, the new total daily dose is $833$ mg.\n\nCaveats for proportional trough-based adjustment in TKIs:\n- Assumption of linear PK may be violated at higher exposures due to saturable absorption, transporter-mediated efflux, or concentration-dependent protein binding. If $F$ or $CL$ changes with dose, the relationship $C \\propto D$ does not hold.\n- Time-dependent kinetics (autoinduction or auto-inhibition of metabolism) can alter $CL$ after dose changes, making the proportionality transient or inaccurate.\n- Drug-drug interactions are common for TKIs (many are substrates of cytochrome P450 3A4 and transporters). Concomitant inhibitors or inducers can change $CL$ or $F$, uncoupling trough from dose.\n- Trough sampling must be truly pre-dose at steady state. Early or late sampling relative to the dose, recent missed doses, or variable adherence can bias $C_{\\min}$.\n- Analytical and inter-occasion variability in therapeutic drug monitoring (TDM; therapeutic drug monitoring) assays introduce measurement error; repeating measurements may be prudent before large dose changes.\n- Active metabolites and pharmacodynamics: some TKIs have active metabolites or target engagement that correlates better with area under the curve (AUC) rather than trough; targeting $C_{\\min}$ may not fully capture exposure-response.\n- Safety considerations: a multiplicative increase by approximately $2.08$ could increase toxicity risk. Clinical practice often uses incremental titration within available tablet strengths, with close monitoring for adverse events and rechecking concentrations.\n\nGiven the problem’s directive to ignore dosage form constraints and provide a single calculated dose, the proportional calculation yields $833$ mg as the target total daily dose to aim for $1250$ ng/mL under the stated assumptions.",
            "answer": "$$\\boxed{833}$$"
        }
    ]
}